抗血管生成疗法的耐药机制及第三代抗血管生成候选药物的研发
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.
作者信息
Loges Sonja, Schmidt Thomas, Carmeliet Peter
机构信息
Vesalius Research Center (VRC), Leuven, Belgium.
出版信息
Genes Cancer. 2010 Jan;1(1):12-25. doi: 10.1177/1947601909356574.
Abstract
The concept of inhibiting tumor neovessels has taken the hurdle from the bench to the bedside and now represents an extra pillar of anticancer treatment. So far, anti-angiogenic therapy prolongs survival in the order of months in some settings while failing to induce a survival benefit in others, in part because of intrinsic refractoriness or evasive escape. This review provides an update on recent mechanisms via which tumor and stromal cells induce resistance and discusses recent evolutions in the (pre)clinical development of novel third-generation anti-angiogenic agents to overcome this problem.
摘要
抑制肿瘤新生血管的概念已跨越从实验室到临床应用的障碍，如今成为抗癌治疗的又一重要支柱。到目前为止，抗血管生成疗法在某些情况下能将生存期延长数月，而在其他情况下则无法带来生存获益，部分原因是存在内在难治性或逃避现象。本综述提供了关于肿瘤和基质细胞诱导耐药的最新机制的最新信息，并讨论了新型第三代抗血管生成药物在（临床前）临床开发中为克服这一问题的最新进展。
相似文献
1
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.抗血管生成疗法的耐药机制及第三代抗血管生成候选药物的研发
Genes Cancer. 2010 Jan;1(1):12-25. doi: 10.1177/1947601909356574.
2
Compensatory angiogenesis and tumor refractoriness.代偿性血管生成与肿瘤难治性
Oncogenesis. 2015 Jun 1;4(6):e153. doi: 10.1038/oncsis.2015.14.
3
Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.逃避肿瘤的逃避：抗血管生成癌症治疗的当前概念和观点。
Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Epub 2010 Jan 12.
4
The role of tumor microenvironment in resistance to anti-angiogenic therapy.肿瘤微环境在抗血管生成治疗耐药性中的作用。
F1000Res. 2018 Mar 15;7:326. doi: 10.12688/f1000research.11771.1. eCollection 2018.
5
Role of the tumor stroma in resistance to anti-angiogenic therapy.肿瘤基质在抗血管生成治疗中的作用。
Drug Resist Updat. 2016 Mar;25:26-37. doi: 10.1016/j.drup.2016.02.002. Epub 2016 Feb 24.
6
Redundant angiogenic signaling and tumor drug resistance.冗余的血管生成信号与肿瘤耐药性
Drug Resist Updat. 2018 Jan;36:47-76. doi: 10.1016/j.drup.2018.01.002. Epub 2018 Jan 17.
7
Cancer anti-angiogenic therapy.癌症抗血管生成疗法。
Biol Pharm Bull. 2004 May;27(5):599-605. doi: 10.1248/bpb.27.599.
8
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment.高危多发性骨髓瘤：综合临床与组学方法剖析肿瘤克隆与肿瘤微环境
J Clin Med. 2019 Jul 9;8(7):997. doi: 10.3390/jcm8070997.
9
Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.针对肿瘤微环境设计和开发新型抗血管生成药物以抑制肿瘤生长。
Prog Biophys Mol Biol. 2013 Nov;113(2):333-54. doi: 10.1016/j.pbiomolbio.2013.10.001. Epub 2013 Oct 15.
10
Trends and Challenges in Tumor Anti-Angiogenic Therapies.肿瘤抗血管生成治疗的趋势和挑战。
Cells. 2019 Sep 18;8(9):1102. doi: 10.3390/cells8091102.
引用本文的文献
1
Angiogenesis-Related Genes Predict Outcomes and Immune Traits in Skin Melanoma.血管生成相关基因可预测皮肤黑色素瘤的预后和免疫特征。
Int J Mol Sci. 2025 Aug 26;26(17):8254. doi: 10.3390/ijms26178254.
2
VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.VEGF信号复杂性赋予EGFR-酪氨酸激酶抑制剂耐药的非小细胞肺癌对阿替利珠单抗、贝伐单抗、卡铂和紫杉醇的抗性。
MedComm (2020). 2025 Aug 19;6(9):e70335. doi: 10.1002/mco2.70335. eCollection 2025 Sep.
3
Detecting vascular normalization in epithelial ovarian cancer.检测上皮性卵巢癌中的血管正常化。
Med Oncol. 2025 Aug 3;42(9):401. doi: 10.1007/s12032-025-02929-5.
4
Angiogenesis related gene signatures predict prognosis and guide therapeutic strategies in renal clear cell carcinoma.血管生成相关基因特征可预测肾透明细胞癌的预后并指导治疗策略。
Sci Rep. 2025 May 16;15(1):17030. doi: 10.1038/s41598-025-02134-4.
5
The potential of miR-29 in modulating tumor angiogenesis: a comprehensive review.miR-29在调节肿瘤血管生成中的潜力：综述
Discov Oncol. 2025 Apr 6;16(1):474. doi: 10.1007/s12672-025-02246-3.
6
Challenges and Opportunities Associated With Drug Delivery for the Treatment of Solid Tumors.实体肿瘤治疗中药物递送所面临的挑战与机遇
Oncol Rev. 2023 Aug 30;17:10577. doi: 10.3389/or.2023.10577. eCollection 2023.
7
YKL-39 is an independent prognostic factor in gastric adenocarcinoma and is associated with tumor-associated macrophage infiltration and angiogenesis.YKL-39 是胃腺癌的独立预后因素，与肿瘤相关巨噬细胞浸润和血管生成有关。
World J Surg Oncol. 2022 Nov 14;20(1):362. doi: 10.1186/s12957-022-02830-9.
8
Integrated Analysis of Multi-Omics Data to Establish a Hypoxia-Related Prognostic Model in Osteosarcoma.多组学数据的综合分析以建立骨肉瘤中缺氧相关的预后模型
Evol Bioinform Online. 2022 Oct 26;18:11769343221128537. doi: 10.1177/11769343221128537. eCollection 2022.
9
Novel Drugs with High Efficacy against Tumor Angiogenesis.新型高效抗肿瘤血管生成药物。
Int J Mol Sci. 2022 Jun 22;23(13):6934. doi: 10.3390/ijms23136934.
10
Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components.卵巢癌球体形成和腹膜转移：基质和免疫成分的作用。
Int J Mol Sci. 2022 Jun 1;23(11):6215. doi: 10.3390/ijms23116215.
本文引用的文献
1
Biomarkers of response and resistance to antiangiogenic therapy.抗血管生成治疗反应和耐药性的生物标志物。
Nat Rev Clin Oncol. 2009 Jun;6(6):327-38. doi: 10.1038/nrclinonc.2009.63.
2
PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment.血小板衍生生长因子C（PDGF-C）在胶质母细胞瘤模型中诱导血管成熟，并减弱对抗血管内皮生长因子（VEGF）治疗的反应。
PLoS One. 2009;4(4):e5123. doi: 10.1371/journal.pone.0005123. Epub 2009 Apr 8.
3
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.用强效肿瘤血管生成抑制剂进行短期治疗后转移加速。
Cancer Cell. 2009 Mar 3;15(3):232-9. doi: 10.1016/j.ccr.2009.01.021.
4
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.抗血管生成疗法会引发肿瘤的恶性进展，导致局部侵袭增加和远处转移。
Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027.
5
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.用血管内皮生长因子抑制剂抑制或促进转移：重新审视抗血管生成
Cancer Cell. 2009 Mar 3;15(3):167-70. doi: 10.1016/j.ccr.2009.02.007.
6
Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature.内皮祖细胞及其他骨髓来源细胞在肿瘤血管生成中的作用。
Angiogenesis. 2009;12(2):159-64. doi: 10.1007/s10456-009-9135-7. Epub 2009 Feb 17.
7
Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.PHD2杂合性缺陷通过内皮细胞正常化恢复肿瘤氧合并抑制转移。
Cell. 2009 Mar 6;136(5):839-851. doi: 10.1016/j.cell.2009.01.020. Epub 2009 Feb 12.
8
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.肾细胞癌中产生精氨酸酶I的髓源性抑制细胞是活化粒细胞的一个亚群。
Cancer Res. 2009 Feb 15;69(4):1553-60. doi: 10.1158/0008-5472.CAN-08-1921. Epub 2009 Feb 5.
9
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.转移性结直肠癌的化疗、贝伐单抗和西妥昔单抗
N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268.
10
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.贝伐单抗联合紫杉醇治疗HER-2阴性转移性乳腺癌的经济学评估
Eur J Cancer. 2009 May;45(8):1397-406. doi: 10.1016/j.ejca.2008.12.016. Epub 2009 Jan 13.
Zotero 插件